Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemiaAnna Guidetti, Alessandro M. Gianni, Corrado Tarella et al.|Cancer|2011Cited by 28
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancerArianna Giacomini, Roberto Ronca|Experimental Hematology and Oncology|2023Cited by 13
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.Anna Guidetti, Alessandro M. Gianni, Alessandra Risso et al.|Blood|2010Cited by 1